Ensoma Announces $85 Million Financing And Agreement To Acquire Twelve Bio To Advance Portfolio Of In Vivo Engineered Cellular Medicines

Jan 05, 2023•almost 3 years ago

Amount Raised

$85 Million

BostonBiotechnologyHealth Care

Investors

Mirae AssetSolasta VenturesCatalio Capital ManagementQatar Investment AuthorityAlexandria Venture InvestmentsTakeda Ventures, Inc.Viking Global InvestorsCormorant Asset ManagementF Prime Capital5 Am VenturesArix Bioscience And 5 Am Ventures

Description

Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its EngeniousTM in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.

Company Information

Company

Ensoma

Location

Boston, Massachusetts, United States

About

Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through in vivo hematopoietic stem cells (HSCs) engineering. Our platform combines proprietary base editing or high-efficiency gene integration systems with high-capacity virus-like particles (VLPs) toward our goal of providing one-time administration of durable genetic medicines. The delivery system is based on VLPs that preferentially bind to HSCs, delivering DNA to the nucleus. With a 35-kilobase cargo capacity, these VLPs can carry a diverse range of sophisticated genomic engineering tools capable of introducing changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression. Ensoma is supported by top-tier investors and a passionate team committed to a bold, global vision for genetic medicines.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends